“PO-75 | Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients With Episodic Migraine After Including CHALLENGE-MIG Trial: Jessica Ailani,1 Pranav Gandhi,2 Anjana Lalla,2 Peter McAllister,3 Tanya Bilchik,4 Stephanie Nahas,5 David Rowe,6 Cristiano Piron,6 Kari Kelton,6 Raffaello Masselli*, Rashmi Halker Singh7 | 1MedStar Health, Washington DC, USA; 2AbbVie, North Chicago, IL, USA; 3New England Institute for Neurology and Headache, Stamford, CT USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA; 6Medical Decision Modeling Inc., Indianapolis, IN, USA; 7Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy. This Individual Has Been Added to This Publication Author by-Line, With the Permission of the Original Authors, for the Express Purpose of Conducting the Presentation at a Local Congress or in a Local Language. He Did Not Contribute to the Content of the Publication”. 2025. Confinia Cephalalgica 35 (S1). https://doi.org/10.4081/cc.2025.15899.